Helpful Products for GLP-1 Treatment
Managing your GLP-1 medication is easier with the right tools:
-
Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
-
Ginger products — Manage nausea with ginger chews or ginger tea.
-
Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
-
Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.
CagriSema is a new medication in development from Novo Nordisk — the same company that makes Wegovy. It builds on Wegovy by adding a second drug to the mix. Phase 3 trial results show it produces meaningfully more weight loss than semaglutide alone.
Quick Comparison
| Wegovy | CagriSema | |
|---|---|---|
| Active drug | Semaglutide 2.4 mg | Semaglutide 2.4 mg + Cagrilintide 2.4 mg |
| Drug class | GLP-1 agonist | GLP-1 + Amylin agonist |
| FDA approval | Weight management (approved) | In FDA review (decision expected late 2026/early 2027) |
| Dosing | Once weekly | Once weekly |
| Avg weight loss | ~15% | 20.4% (REDEFINE 1, non-diabetes) |
| Status | Available now | Not yet FDA-approved |
What Makes CagriSema Different?
CagriSema combines:
- Semaglutide — the same drug in Wegovy (GLP-1 agonist)
- Cagrilintide — an amylin receptor agonist that also signals fullness
Two fullness signals instead of one. That's the idea. Semaglutide reduces appetite and slows stomach emptying through the GLP-1 pathway. Cagrilintide adds a second signal through the amylin pathway — a hormone your body naturally releases after eating to tell your brain you're full.
Weight Loss Results
The Phase 3 REDEFINE program provides the most complete comparison data:
REDEFINE 1 (People Without Diabetes)
- CagriSema: 20.4% average weight loss over 68 weeks
- Semaglutide 2.4 mg alone: 14.9% average weight loss
- Cagrilintide 2.4 mg alone: 11.5% average weight loss
- Placebo: 3.0%
About 37% of people on CagriSema lost 25% or more of their body weight.
REDEFINE 2 (People With Type 2 Diabetes)
- CagriSema: 13.7% average weight loss over 68 weeks
- Placebo: 3.1%
Weight loss was lower in the diabetes group, which is typical for GLP-1 trials. People with type 2 diabetes tend to lose less weight than people without diabetes on the same medication.
What This Means for the Comparison
CagriSema beats Wegovy by roughly 5-6 percentage points of body weight loss. That's a meaningful difference — not just a small margin. For a 200 lb person, that could mean losing an additional 10-12 lbs over 68 weeks.
How CagriSema Compares to Other Options
| Drug | Avg Weight Loss | Dosing | Status |
|---|---|---|---|
| CagriSema | 20.4% (non-diabetes) | Weekly injection | FDA review (decision late 2026/early 2027) |
| Zepbound (tirzepatide) | 15-21% | Weekly injection | FDA approved |
| Wegovy (semaglutide) | ~15% | Weekly injection | FDA approved |
| Foundayo (orforglipron) | ~11% | Daily pill | FDA approved (Apr 2026) |
CagriSema's 20.4% result puts it alongside Zepbound at its highest dose. The SURMOUNT trials showed up to 21% weight loss for Zepbound, so the numbers are very close. CagriSema uses a different mechanism (GLP-1 + amylin) compared to Zepbound (GLP-1 + GIP). For some people, one approach may work better than the other.
Side Effects
Based on trial data, CagriSema causes similar side effects to Wegovy:
- Nausea
- Decreased appetite
- Vomiting
- Diarrhea or constipation
- Stomach pain
About 10-15% of people discontinued treatment due to side effects in the REDEFINE trials — similar to Wegovy. Because CagriSema hits two pathways, some people may experience stronger side effects, but the overall discontinuation rate was comparable.
Availability and FDA Timeline
CagriSema is not yet FDA-approved. Novo Nordisk submitted its FDA application in late 2025. The FDA review timeline is typically 10-12 months for standard review.
Expected FDA decision: Late 2026 or early 2027. If approved, CagriSema would likely launch in 2027. Novo Nordisk has also applied for approval in Europe through the EMA.
Cost
No pricing yet. Based on the current market:
- Likely priced at a premium over Wegovy since it's a new combination
- Probably around $1,200/month before insurance
- Novo Nordisk's savings card program will likely apply
- Insurance coverage will take time — expect prior authorization requirements
Who Might Benefit?
CagriSema may be a good option for:
- People who plateaued on Wegovy and need more weight loss
- People who didn't tolerate tirzepatide (Zepbound) well
- People who prefer Novo Nordisk products
- People who want results similar to Zepbound but through a different mechanism
It may NOT be worth switching if:
- You're already happy with your current weight loss on Wegovy
- You're doing well on Zepbound (which has similar weight loss numbers)
- Cost is a major concern (it will likely be expensive at launch)
Bottom Line
CagriSema's Phase 3 results are stronger than Wegovy's. The REDEFINE 1 trial showed 20.4% weight loss — about 5-6% more than semaglutide alone. That puts it in the same range as Zepbound.
The FDA decision is expected in late 2026 or early 2027. For now, Wegovy, Zepbound, and Foundayo remain your available options. If Wegovy is working for you now, there's no reason to wait. If you're not getting the results you want, talk to your doctor about current options — including Zepbound, which is available now with similar weight loss numbers.
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary. Last updated: June 3, 2026.
Related Reading
- CagriSema: What It Is, Trial Results, and When It's Coming
- Wegovy vs Zepbound: Which Weight Loss Drug Is Better?
- Foundayo vs Wegovy: Pill vs Injection for Weight Loss
- Ozempic vs CagriSema: What to Know
- Retatrutide Guide: Phase 3 Results and What Comes Next
- Mounjaro vs Wegovy: Which Is Better for Weight Loss?
